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within the first 6 months of life standardized to WHO growth 
standards. Weight change was regressed on each of 168 me-
tabolites (acylcarnitines, lysophosphatidylcholines, sphingo-
myelins, and amino acids). Metabolites significant after Bon-
ferroni’s correction were tested as predictors of later over-
weight/obesity.  Results: Among the overall 19 significant 
metabolites, 4 were associated with rapid growth and 15 
were associated with a less-than-ideal weight change. After 
adjusting for feeding group, only the lysophosphatidylcho-
line LPCaC14: 0 remained significantly associated with rapid 
weight gain (β = 0.18). Only LPCaC14: 0 at age 6 months was 
predictive of overweight/obesity at age 6 years (OR 1.33; 95% 
CI 1.04–1.69).  Conclusion: LPCa14: 0 is strongly related to rap-
id growth in infancy and childhood overweight/obesity. This 
suggests that LPCaC14: 0 levels may represent a metabolically 
programmed effect of infant weight gain on the later obesity 
risk. However, these results require confirmation by indepen-
dent cohorts.  © 2014 S. Karger AG, Basel 
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 Abstract 
 Background: Despite the growing interest in the early-ori-
gins-of-later-disease hypothesis, little is known about the 
metabolic underpinnings linking infant weight gain and 
childhood obesity.  Objective: To discover biomarkers reflec-
tive of weight change in the first 6 months and overweight/
obesity at age 6 years via a targeted metabolomics approach. 
 Design: This analysis comprised 726 infants from a European 
multicenter randomized trial (Childhood Obesity Programme, 
CHOP) for whom plasma blood samples at age 6 months and 
anthropometric data up to the age of 6 years were available. 
‘Rapid growth’ was defined as a positive difference in weight 
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 Early rapid growth has been well established as a risk 
factor for later obesity since the salient paper of Ong et al. 
 [1] on catch-up growth made this hypothesis a prominent 
issue  [2] . It has been proposed that adverse programming 
of the metabolic profile by early nutrition in postnatal life 
may be behind these associations  [3] . A recent review em-
phasized the role of the first 6 months of life in adverse 
programming of the metabolic profile in infants as the 
main biological underpinning of such a link  [4] . In es-
sence, this review concludes that the biological mecha-
nisms linking infant weight gain to child obesity via met-
abolic programming are due to metabolic characteristics 
of the given human or formula milk affecting the meta-
bolic, immunological, and anthropometric response of 
the infant. Although this review is very informative, it 
documents that, in contrast to the literature on adults  [5, 
6] , the power of metabolomics still needs to be fully uti-
lized in pediatrics beyond clinical settings in neonatology 
 [7, 8] . Metabolomics has a great potential for the discov-
ery of biomarkers reflective of weight gain and obesity via 
examination of alterations in amino acid and lipid me-
tabolism  [5–8] .
 A few studies have applied a targeted metabolomics 
approach for the analysis of obesity or weight change in 
child or adolescent populations  [9–12] . These publica-
tions have mainly been based on small case-control stud-
ies of obese and normal-weight children, with a maxi-
mum of 160 participants in late childhood or adolescence 
from clinical settings or even very special populations like 
anorexic patients  [9] . The metabolic profile of weight 
change has therefore only been assessed in the context of 
obesity or anorexia treatment, resulting in the analysis of 
weight loss  [12] and weight regain  [9] , and not in un-
selected populations. Thus, the metabolic profile of an-
orexic patients with a mean age of about 15 years  [9] is 
quite different and comprises more metabolites from 
more species than those found in studies on obese versus 
normal-weight children and adolescents with an age 
range of 6–16 years  [11, 12] .
 In obese adults, elevated ratios of amino acids to cor-
responding short-chain acylcarnitines were reported by 
Newgard et al.  [13] . However, a US study could not con-
firm these findings in obese or diabetic youth  [10] and 
rejected the hypothesis of impaired fatty acid or amino 
acid metabolism as a driving force of obesity in youth. 
Instead, the hypothesis of a ‘failure of mitochondrial 
adaptive mechanisms’ in obesity and diabetes is proposed 
for both adults and adolescents. According to those au-
thors, difficulties showing this general mechanism in the 
obese adolescents in that study contributed to a lack of 
duration of obesity or diabetes. However, that study was 
based only on 39 normal-weight, 64 obese, and 17 adoles-
cent subjects with type 2 diabetes  [10] .
 Despite the above-mentioned evidence of the impor-
tance of the first 6 months of life for programming of the 
metabolic profile, weight development, and obesity risk 
of a child, no large unselected population-based study fol-
lowing a comprehensive targeted metabolomics approach 
has been published so far for this age group. The Euro-
pean Childhood Obesity Programme (CHOP) study, a 
randomized prospective nutritional intervention study 
following formula-fed infants with a high or low protein 
intake, is well suited to investigating the metabolic profile 
in relation to weight change in infants and older children 
 [14–17] . Moreover, using WHO growth standards  [18] , a 
more-than-ideal weight gain (‘rapid growth’) as well as a 
less-than-ideal weight gain can be assessed and related to 
the infant’s metabolic markers. In addition, this study 
comprises an ongoing birth cohort and enables evalua-
tion of the predictive effect of metabolic markers for de-
velopment of overweight and obesity at the age of 6 years 
in a genuine longitudinal study. Thus, this study may 
contribute to reducing the ‘causal dilemma’ of metabolo-
mics analysis regarding the cause and effect of changes in 
growth and changes in metabolites.
 The aims of this study are therefore: (1) to investigate 
whether changes in weight in the first 6 months of life are 
related to levels of amino acids or lipid metabolites using 
a comprehensive targeted metabolomics approach, and 
(2) to assess which of these metabolites are also associated 
with obesity in later childhood at age 6 years.
 Answers to such questions may give further insight 
into the biological underpinnings of the ‘accelerated post-
natal growth hypothesis’ – in particular with respect to 
the role of metabolic programming of growth and later 
obesity  [3] .
 Material and Methods 
 Subjects and Procedures 
 This analysis is based on a subsample of 726 of the 1,678 infants 
recruited in the first 8 weeks of life for the European CHOP study 
for whom plasma blood samples for metabolic profiling at the age 
of 6 months and anthropometric data at birth and 6 months were 
available. Among these, 394 children also had anthropometric data 
at the age of 6 years. The CHOP study is an ongoing randomized 
nutritional intervention trial and birth cohort of formula-fed in-
fants randomized to a high- or low-protein content formula and 
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Italy, Poland, and Spain). Details of the CHOP study design and 
procedures have been published previously  [14–17] . The study fol-
lowed the recommendations made in the CONSORT statement 
 [19] and was approved by the ethics committees of all participating 
study centers, and written informed parental consent was obtained 
for each infant.
 Measurement of Metabolites 
 For 764 infants aged 6 months, plasma samples were drawn for 
metabolite analyses in all study centers (except the center in Milan, 
Italy, which had not received ethical approval for blood sampling). 
Parents were asked not to feed their infants for at least 2 h before 
the blood draw. Drawn plasma samples were stored at –80  °  C, ex-
cept at the study center in Belgium, where samples were stored at 
–20   °   C. Measurements were performed at the Munich laboratory 
(Division of Metabolic and Nutritional Medicine, Dr. von Hauner 
Children’s Hospital).
 Analyses were performed to quantify 168 known lipid metabo-
lites and amino acids. Amino acids were analyzed by liquid chro-
matography coupled to either ultraviolet detection  [16] or mass 
spectrometry  [20] . Lipid and hexose (90–95% glucose) analyses 
were performed by flow injection mass spectrometry using a 
Biocrates AbsoluteIDQ p150 kit (Biocrates Life Sciences AG, Inns-
bruck, Austria), which has been utilized previously for targeted 
metabolomics studies in children  [11, 12] . The following lipid 
groups (number of metabolites) were determined: acylcarnitines 
(41), phosphatidylcholines (76), lysophosphatidylcholines (15), 
sphingomyelins (14, including 5 hydroxy-sphingomyelins), and 
21 amino acids.
 Outcome Definition 
 Weight change was defined as the difference between the 
weight at age 6 months and the birth weight. Weight measure-
ments were transformed to age- and sex-specific WHO growth 
standards before subtraction to account for gender differences 
as well as deviations in the date of measurement and to allow 
interpretation of weight change differences as above or below 
the ‘ideal’ weight gain. As values of these WHO weight stan-
dards are designed to indicate the ideal weight at a specific age 
for the respective gender  [18] , a positive value for the differ-
ences of these standardized weight measurements indicates a 
higher-than-ideal velocity of weight gain (rapid growth), and a 
value below 0 for such a weight change slope could be interpret-
ed as a less-than-ideal weight gain. Overweight or obesity at age 
6 years is used as a distal outcome and is related to the metabo-
lites are associated with infant weight change defined above. 
Overweight or obesity was defined as a body mass index (BMI) 
percentile of 90 or above and was derived from weight and 
height transformations according to WHO growth references 
for school-aged children and adolescents  [21] . Note that a 
WHO-transformed BMI-SDS >1.28 is equivalent to the 90th 
percentile or above and was used as the cutoff point for the in-
dicator-coded variable (1 vs. 0).
 Statistical Analysis 
 A mainly explorative analysis approach with several steps 
was applied. In step 1, standard bivariate regression was applied 
to regress the WHO-standardized weight change outcome on 
each of the 168 measured metabolites. Each metabolite was 































Girls 141 3,226 321 138 3,226 345 98 3,299 332 377 3,245 333
Boys 134 3,337 328 139 3,336 349 76 3,432 408 349 3,357 356
Mothers 203 3,280 595 208 3,281 599 150 3,237 597 561 3,269 596
Fathers 178 3,396 620 180 3,566 624 130 3,487 567 488 3,483 611
Birth length (cm)
Girls 141 50.5 2.8 138 50.3 2.6 98 50.8 2.5 377 50.5 2.6
Boys 133 51.2 2.8 139 51.3 3.0 76 51.9 3.2 348 51.4 3.0
Prepregnancy BMI
Mothers 271 23.7 4.5 273 23.9 4.8 171 22.5 3.7 715 23.5 4.5
Fathers 263 26.2 3.8 267 26.1 3.7 170 25.9 3.4 700 26.1 3.7
Gestational age (weeks) 275 39.8 1.1 277 39.9 1.2 173 40.0 1.2 725 39.9 1.2
Any maternal smoking
during pregnancy 132/274 48.2% 42.2–54.1 117/276 42.4% 36.5–48.3 26/174 14.9% 9.6–20.3 275/724 38.0% 34.4–41.5
Parental education
Low 66/275 24.0% 18.9–29.1 57/277 20.6% 15.8–25.4 8/174 4.6% 1.5–7.7 131/726 18.0% 15.2–20.8
Medium 148/275 53.8% 47.9–59.7 156/277 56.3% 50.4–62.2 46/174 26.4% 19.8–33.1 350/726 48.2% 44.6–51.9
High 61/275 22.2% 17.2–27.1 64/277 23.1% 18.1–28.1 120/174 69.0% 62.0–75.9 245/726 33.7% 30.3–37.2
Country 
Germany 57/275 20.7% 15.9–25.5 62/277 22.4% 17.4–27.3 48/174 27.6% 20.9–34.3 167/726 23.0% 19.9–26.1
Belgium 35/275 12.7% 8.8–16.7 32/277 11.6% 7.8–15.3 34/174 19.5% 13.6–25.5 101/726 13.9% 11.4–16.4
Poland 76/275 27.6% 22.3–33.0 77/277 27.8% 22.5–33.1 44/174 25.3% 18.8–31.8 197/726 27.1% 23.9–30.4
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transformed to a standard normal distribution with a mean of 0 
and a variance of 1 to account for the different measurement 
scale ranges and thus ease the evaluation of the effect sizes. In 
step 2, weight change-related metabolites were identified by 
Bonferroni-corrected p values [threshold 3.53 = –log 10 (0.05/168)] 
and illustrated using a Manhattan plot. The effect sizes, cor-
rected p values on the –log 10 (p) scale, and explained variances 
of weight change for these significant metabolites are listed in 
table 2. In step 3, the potential associations of significant me-
tabolites with the outcome of BMI-SDS-defined overweight or 
obesity at age 6 years were explored by standard logistic regres-
sion.
 All analyses were repeated with adjustment for feeding group 
(i.e. including the 2 indicator-coded variables low-protein feeding 
group and high-protein feeding group with the implicit reference 
group breast-fed) in analysis steps 1 and 2 to account for potential 
differences due to the study design. All statistical analyses were 
conducted using the software SAS 9.3 [22] .
 Results 
 The characteristics of the analyzed population are list-
ed in  table 1 . No substantial differences were observed for 
offspring’s birth weight, birth length, or gestational age 
among the randomized groups of low- or high-protein 
formula, and there were no statistical differences in the 
mother’s birth weight, maternal or paternal prepregnan-
cy BMI or maternal smoking during pregnancy, parental 
educational level, or the relative composition of the study 
population by study center among these feeding groups. 
 The father’s birth weight was lower for the low-protein 
formula group compared to the group fed the high-pro-
tein formula. However, we do not consider this difference 
to be so substantial that the randomization of the formu-





































 Fig. 1. Metabolites and weight change in the first 6 months of life 
(Manhattan plot, crude model). Note: metabolites were trans-
formed to a standard normal distribution (X ∼ N[0; 1]). Weights at 
birth and at age 6 months were standardized to WHO growth stan-
dards before calculation of weight change. Weight change is the 
outcome regressed on each metabolite separately without any ad-
justment. Cx:y represents an acyl group with chain length x and y 
double bonds. PCaa = Diacyl-phosphatidylcholine; PCae = acyl-
akyl-phosphatidylcholine; LPCa = lysophosphatidylcholine with 




















   
   
   
   
   
   
   
   
   
   
   





















 Rzehak   et al.
 
 Ann Nutr Metab 2014;64:294–303 
DOI: 10.1159/000365037
298
sider the differences in most of these characteristics 
among the breast-fed group and the formula-fed groups 
a problem regarding randomization as the breast-fed 
group was included only as an observational group in the 
CHOP cohort and consequently did not affect random-
ization. Nevertheless, associations of metabolites with 
weight change were also reported after adjustment for 
feeding group (see below) because there are clear differ-
ences in metabolite profiles among feeding groups in the 
CHOP study.
 All p values of the 168 unadjusted regressions of the 
outcome WHO-standardized weight change in the first 6 
months on each of the standard-normalized metabolites 
(see Materials and Methods) are depicted in a Manhattan 
plot style figure with all Bonferroni-corrected significant 
metabolites labeled ( fig. 1 ). The size and direction of the 
effect, significance level, and explained variance are listed 
in  table  2 . The amino acids tyrosine and citrulline, the 
diacyl-phosphatidylcholine PCaaC34: 4, and the lyso-
phosphatidylcholine LPCaC14: 0 were the only metabo-
lites that resulted in a higher-than-ideal weight gain (rap-
id growth) during the first 6 months of life. All other 15 
significant metabolites of the overall 19 significant ones 
showed a negative effect on the infants’ weight change 
(lower-than-ideal weight gain). That is, 5 short- or long-
chain acylcarnitines [C5:M(DC), C6: 1, C16: 1(OH),
C18: 0, and C18: 1(OH)], 8 acyl-alkyl-phosphatidylcho-
lines (PCaeC34: 0, PCaeC36: 0, PCaeC38: 0, PCaeC38: 4, 
PCaeC38: 6, PCaeC40: 0, PCaeC40: 5, and PCaeC40: 6), 1 
hydroxy-sphingomyelin [SMC16: 1(OH)], and 1 sphin-
gomyelin (SMC26: 1) were inversely related to weight 
change, indicating a somewhat flatter-than-ideal growth 
trajectory in the first 6 months of life.
 It is interesting to note that the lysophosphatidylcho-
line LPCaC14: 0, with 4.3%, explained by far the most 
variance of infant weight change, followed by the acyl-
carnitine C16: 1(OH) with 3.3% and the acyl-alkyl-phos-
phatidylcholine PCaeC34: 0 with 3%. However, only








TYR 0.16 4.8 2.6
CIT 0.15 4.3 2.2
Acylcarnitines
C5:M(DC) –0.14 4.1 2.1
C6:1 –0.15 4.7 2.5
C16:1(OH) –0.18 6.0 3.3
C18:0 –0.16 4.9 2.6
C18:1(OH) –0.14 3.8 2.0
Phosphatidylcholines
Diacyl-phosphatidylcholines
PCaaC34:4 0.14 3.7 1.9
Acyl-akyl-phosphatidylcholines
PCaeC34:0 –0.17 5.5 3.0
PCaeC36:0 –0.15 4.5 2.4
PCaeC38:0 –0.14 3.8 2.0
PCaeC38:4 –0.13 3.6 1.8
PCaeC38:6 –0.13 3.6 1.8
PCaeC40:0 –0.13 3.6 1.9
PCaeC40:5 –0.14 3.9 2.0
PCaeC40:6 –0.15 4.5 2.4
Lysophosphatidylcholines
LPCaC14:0 0.20 7.7 4.3
Hydroxy-sphingomyelins
SMC16:1(OH) –0.16 4.9 2.6
Sphingomyelins
SMC26:1 –0.13 3.7 1.9
 Only metabolites significantly related to weight change resul-
ting from unadjusted linear regression are listed. Cx:y represents 
an acyl group with chain length x and y double bonds. PCaa = 
diacyl-phosphatidylcholine; PCae = acyl-akyl-phosphatidylcho-
line; LPCa = lysophosphatidylcholine with an acyl chain; TYR = 








































































 Fig. 2. Association of significant metabolites and overweight/obe-
sity at age 6 years (OR with 95% CI estimated by logistic regression, 
crude model). Cx:y represents an acyl group with chain length x 
and y double bonds. PCaa = Diacyl-phosphatidylcholine; PCae = 
acyl-akyl-phosphatidylcholine; LPCa = lysophosphatidylcholine 
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LPCaC14: 0 was significantly and strongly positively as-
sociated with overweight or obesity at age 6 years in these 
crude analyses ( fig. 2 ). For higher levels of the acylcarni-
tine C6: 1, the odds of overweight or obesity were substan-
tially reduced, but this association just failed to be sig-
nificant. All other weight change-related metabolites 
were clearly not associated with overweight or obesity at 
the age of 6 years ( fig. 2 ). 
 Repeating these regressions with adjustment for feed-
ing group to account for known differences in metabo-
lite levels among the feeding groups in this study result-
ed in only 2 metabolites with a significant effect on
infant weight change: the diacyl-phosphatidylcholine 
PCaaC38: 3 and the lysophosphatidylcholine LPCaC14: 0 
( table 3 ). Both metabolites are positively associated with 
a higher-than-ideal weight gain (rapid growth) and ex-
plain a substantial part of the weight gain variance 
(about 6.7 and 7.8%, respectively). It is interesting to 
note that LPCaC14: 0 had a significant positive relation 
with the highest effect size already in the crude analyses, 
whereas PCaaC38: 3, though it showed a positive effect 
size (β = 0.10), was not significant even without adjust-
ment for feeding group after Bonferroni’s correction for 
multiple testing. Moreover, LPCaC14: 0 is the only me-
tabolite that resulted in a significant and substantial as-
sociation with overweight or obesity at age 6 years after 
adjustment.
 Discussion 
 Exploration of the relationship of 168 metabolites of 
amino acid and lipid metabolism and weight change 
from birth up to age 6 months in this large prospective 
unselected cohort for 726 children revealed that 19 me-
tabolites showed significant effects on infant weight 
change. Remarkably, only the amino acids tyrosine and 
citrulline, the diacyl-phosphatidylcholine PCaaC34: 4, 
and the lysophosphatidylcholine LPCaC14: 0 were relat-
ed to higher-than-ideal weight gain (rapid growth) dur-
ing the first 6 months of life. All other 15 significant 
metabolites, i.e. 5 short- or long-chain acylcarnitines 
[C5:M(DC), C6: 1, C16: 1(OH), C18: 0, and C18: 1(OH)], 
8 acyl-alkyl-phosphatidylcholines (PCaeC34:  0, 
PCaeC36:  0, PCaeC38:  0, PCaeC38:  4, PCaeC38:  6, 
PCaeC40: 0, PCaeC40: 5, and PCaeC40: 6), 1 hydroxy-
sphingomyelin [SMC16: 1(OH)], and 1 sphingomyelin 
(SMC26: 1) were associated with a lower-than-ideal 
weight gain in this 6-month period after correcting for 
multiple testing. 
 Our finding of a positive relation of tyrosine with rap-
id growth is in line with the results of one of the few lon-
gitudinal studies on metabolic profiles in youth which 
showed elevated levels of tyrosine after a quick weight 
recovery for adolescent anorexia patients  [9] . A small 
study in healthy prepubertal and pubertal children with 
a focus on analysis of fasting circulating concentrations 
of branched-chain amino acids and potential insulin re-
sistance 18 months after enrolment gave further, though 
indirect, plausibility to our finding by showing a positive 
correlation with fasting BMI-SDS and a greater effect on 
future HOMA insulin resistance not far from signifi-
cance  [23] . However, in contrast to our study, citrulline 
was negatively related to both BMI-SDS and future 
HOMA insulin resistance in that and another study in 
youth  [10, 23] . Rapid weight gain was also associated 
with levels of PCaaC34: 4 in a longitudinal study in ado-
lescent anorexia patients  [9] . We could not identify fur-
ther studies showing this effect either in youth or in 
younger children. However, this may be due to the lack 
of comprehensive metabolomics studies in children.
 Our findings of a negative relation with rapid weight 
gain for some short- and long-chain acylcarnitines were 
only partly in line with those of the longitudinal study in 
anorexia patients  [9] . The same is true regarding our re-
sults on short-chain acylcarnitines. However, in a cross-
sectional study, a negative relation of C5 and C6 acylcar-
nitines with BMI in normal-weight, obese, and type 3 
diabetes youth was shown  [10] . Our results regarding a 
negative relation of rapid weight gain and levels of acyl-
akyl-phosphatidylcholines are also mixed. Only for 
PCaeC36: 0, PCaeC38: 6, PCaeC40: 5, and PCaeC40: 6 
were these previous results in line with our findings. A 
negative relation to rapid weight gain as in our study was 
found for the sphingomyelin SMC26: 1, but not for
the hydroxy-sphingomyelin SMC16: 1(OH)  [9] . After 
accounting for feeding group (high- or low-protein
formula or fully breast-fed), only LPCaC14: 0 and
 Table 3.  Metabolites, weight change, and overweight/obesity after 







OR   95% CI
Diacyl-phosphatidylcholines
PCaaC38:3 0.14 5.5 6.7 1.00 0.96–1.04
Lysophosphatidylcholines
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PCaaC38: 3 were positively associated with weight 
change (rapid growth). Interestingly, the latter was not 
significantly associated with weight change in the crude 
analyses. In addition to the relation with infant weight 
change up to the age of 6 months, LPCaC14: 0 was the 
only metabolite which was also strongly and significant-
ly associated (OR 1.33; 95% CI 1.04–1.69) with over-
weight or obesity in infants at the age of 6 years. This 
may suggest that LPCaC14: 0 may be a metabolic marker 
programmed by rapid weight gain. Furthermore, the 
metabolic alterations themselves may underpin further 
weight gain and later obesity. However, disentangle-
ment of this causal conundrum with more certainty 
would require the availability of more longitudinal met-
abolic marker measurements over time. LPCaC14: 0 is 
endogenously synthesized from phospholipase A2 by 
cleaving a fatty acid from the sn-2 position of the glyc-
erol backbone of a diacyl-phosphatidylcholine contain-
ing the myristic acid C14: 0 at the sn-1 position. Lyso-
phosphatidylcholines and the resulting nonesterified 
fatty acid are the suggested form of transport into cells 
 [24] . For example, lysophosphatdylcholine is proposed 
as the primary metabolite facilitating blood docosa-
hexaenoic acid incorporation into the brain  [25] .
 Despite the known importance of the first 6 months 
of life for metabolic programming of weight change  [3, 
4] , we did not find any previously published metabolo-
mics- or otherwise focused studies identifying a rela-
tionship of LPCaC14: 0 with any kind of weight gain in 
the age group of interest, i.e. 6-month-old infants. More-
over, we did not find respective publications in any age 
group. Therefore, we cannot directly evaluate our find-
ing regarding LPCaC14: 0 and more-than-ideal weight 
gain (rapid growth) in the context of previous publica-
tions. Consequently, replication of our finding in an-
other independent cohort is definitely required. Other 
lysophosphatidylcholines have been related to weight 
loss (LPCaC18: 1, LPCaC18: 2, and LPCaC20: 4)  [12] or 
weight regain (LPCaC16: 0, LPCaC16: 1, LPCaC17: 0,
LPCaC18: 0, LPCaC18: 1, LPCaC18: 2, LPCaC20: 3, and 
LPCaC20: 4)  [9] in small longitudinal studies of children 
aged 11 or 15 years, respectively. However, both findings 
resulted from either obesity or anorexia treatment stud-
ies and were additionally based on special interventions 
in special populations. We did not find publications for 
our other main finding that higher LPCaC14: 0 levels are 
associated with overweight or obesity in children at age 
6 years, either.
 Since molecular studies of different LPCa species like 
LPCaC14: 0 are missing, it is difficult to provide a suit-
able explanation for the effect of LPCaC14: 0. LPCa are 
degraded to lysophosphatidic acids (LPA)  [26] , which 
are elevated in obese mice  [27] and influence adipose 
tissue differentiation  [28] . To our knowledge, no studies 
are available investigating the different effects of LPA on 
obesity development. It has only been stated that differ-
ent LPA species have different biological activities on 
LPA receptors  [29] . Thus, we can only raise the question 
of whether LPCaC14: 0 or LPAaC14: 0 has an adverse ef-
fect on human weight gain compared to other LPC or 
LPA species, but more in vitro, in vivo, or tracer studies 
are needed. However, analysis of the total plasma fatty 
acid composition in 59 obese children aged 12 years 
from a Japanese obesity clinic and 53 age- and sex-
matched normal-weight children revealed that C14: 0 – 
the main fatty acid component of LPCaC14: 0 – was el-
evated in obese adolescents  [30] . Thus, our findings are 
indirectly in line with these results. An explicit associa-
tion of elevated LPCaC14: 0 levels with overweight or 
obesity was found only in a South Korean case-control 
study of 60 adult men  [31] . Thus, we may speculate, as 
mentioned above, that elevated levels of LPCaC14: 0 ear-
ly in life may be a weight change-programmed meta-
bolic marker for later obesity. However, more measure-
ments over time for this and pathway-related metabo-
lites would be required to give further evidence for such 
an interpretation.
 Comparable to studies in children, most of the evi-
dence for the role of LPCaC14: 0 in obesity in adults has 
been obtained only via indirect analysis of total or free 
fatty acids. These studies have consistently shown ele-
vated levels of C14: 0 (myristic acid) in adults as well  [13, 
32, 33] . A study on lean, healthy, metabolically healthy, 
and metabolically unhealthy obese adults showed that 
C14: 0 even has a dose-response relationship with the 
status of obesity and according to the degree of obesity-
related inflammation  [33] . Whether this would show up 
also in children with different degrees of obesity or ex-
plicitly for LPCaC14: 0 is an open question. There is also 
evidence that myristic acid (C14: 0) influences the size of 
fat cells  [32] and augments insulin release  [34] . Al-
though most of the reported results on the role of
LPCaC14: 0 regarding weight gain or obesity are only in-
directly based on fatty acid analysis (C14: 0) or adult 
studies, its role as a programmed marker seems not to 
be implausible despite the gaps in the literature. The lack 
of further significant correlating phosphatidylcholines 
containing myristic acid indicates that there is no en-
hanced bioavailability of myristic acid. In the case of en-
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dylcholines should have shown a relation to weight 
change as well. Thus, it seems that a specific relation 
between LPCaC14: 0 and a possible signaling pathway 
might be assumed.
 Strength and Limitations 
 This is, to the best of our knowledge, the first study in 
an unselected and large cohort to examine the metabol-
ic profile of weight change in the potentially develop-
mentally decisive first 6 months of life and relate it to 
overweight or obesity in later childhood as well. Our ex-
ploratory findings of the role of LPCaC14: 0 in weight 
gain and obesity document the usefulness of such a tar-
geted metabolomics approach, in particular for pediat-
rics and obesity research  [7] . If replicated in an indepen-
dent cohort, elevated LPCaC14: 0 levels may prove to be 
an early and weight change-programmed metabolic 
marker for later obesity. Thus, this mainly exploratory 
and easy-to-apply approach may be used as a first step 
in the identification of interesting metabolites before 
complex pathway and functional network analyses are 
performed – similar to what is done using the GWAS 
approach  [35, 36] .
 A potential limitation is that we did not have a base-
line metabolic profile at birth, which could have allowed 
longitudinal analysis of both weight change and meta-
bolic change to reduce the potential causal conundrum 
of whether rapid weight gain affected the metabolic pro-
file at age 6 months or whether the metabolic profile at 
birth or its change in the first 6 months resulted in the 
observed rapid weight change. Although we consider 
analysis of the association of each metabolite one by one 
to be a good start, accounting for metabolic pathways 
and appropriate construction of metabotypes may be a 
useful and even necessary extension in a second, more 
thorough and targeted step of analysis  [35–37] .
 Conclusions 
 The lysophosphatidylcholine LPCaC14: 0 is consis-
tently and strongly related to both rapid weight gain 
during the first 6 months of life and overweight/obe-
sity at age 6 years. This suggests that rapid weight gain 
early in life may not only be associated with altered
LPCaC14: 0 levels but may also represent a metabolical-
ly programmed effect of weight gain on the later obesity 
risk. However, these results require confirmation by in-
dependent cohorts and with longitudinal metabolic 
marker data in addition to the longitudinal anthropo-
metric data at hand. Moreover, a more detailed analysis 
of metabolic pathways and networks would be the next 
step and would strengthen these results further.
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